
~Interim Translation by JGA~ Generics-related extract from *Basic Policy on Economic and Fiscal Management and Reform* 2015 (Cabinet Decision 30th June,2015) chapter3-5-[1]Social Security, pages 33-34

The targeted volume share of generics has been revised from 60% or above by the end of FY 2017 to 70% or above by mid-2017 as a step toward achieving 80% or above, and it is planned to attain the target goal of 80% or above at the earliest date possible between FY 2018 and 2020. A detailed time-table for attaining 80% or above shall be finally set through evaluation of actual progress in volume share of generics by mid-2017.

Additional measures considered necessary to reach the new target will be taken in related fields such as a stable supply, confidence in quality, information provision, and NHI- related matters.

From the viewpoint of decreasing the financial burden on people, the revision of pricing rules for generics will be examined and also the evaluation in the NHI scheme of off-patent originator medicines will be reviewed in consideration of the pricing of generics *etc*.



1) Actual generic volume share from Sept,2005 to Sept,2013 are based on biennial drug price-volume market survey by the Ministry of Health, Labour and Welfare

2) Calculation of generic volume share : Generic share(%) of the Market Replaceable by Generics (=Generics / (Generics + off-patent originator medicines)